Intranasal Cry1Ac Protoxin is an Effective Mucosal and Systemic Carrier and Adjuvant of Streptococcus pneumoniae Polysaccharides in Mice

Scandinavian Journal of Immunology

Volumn 57, Issue 1, 2003, Pages 45-55

  Moreno Fierros, L ^a,b,d   Ruiz Medina, E J ^a   Esquivel, R ^a   Lopez Revilla R ^b,c   Pina Cruz S ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CRY1AC PROTOXIN; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PROTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACILLUS THURINGIENSIS; BACTERIAL IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG ISOLATION; DRUG SYNTHESIS; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACILLUS THURINGIENSIS; BACTERIAL CAPSULES; BACTERIAL PROTEINS; BACTERIAL TOXINS; ENDOTOXINS; FEMALE; HEMOLYSIN PROTEINS; IMMUNITY, MUCOSAL; INJECTIONS, INTRAPERITONEAL; INTESTINE, SMALL; MICE; MICE, INBRED BALB C; POLYSACCHARIDES, BACTERIAL; PROTEIN PRECURSORS;

EID: 0346880531     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01190.x     Document Type: Article

References (58)

1. Toumanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995;332:1280-4.
2. Watson DA, Musher DM, Verhoef J. Pneumococcal virulence factors and host immune responses to them. Eur J Clin Microbiol Infect Dis 1995;14:479-90.
3. Vidarsson G, Jonsdottir I, Jonsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharide of Streptococcus pneumoniae. J Infect Dis 1994;170:592-9.
4. Leinonen M, Sakkinen A, Kalliokoski R. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis J 1986;5:39-44.
5. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995;13:655-92.
6. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
7. Käyhty H, Aahman H, Ronnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
8. Åhman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15:134-9.
9. Elson CJ, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984;132:2736-41.
10. Wilson AD, Stokes CR, Bourne FJ. Adjuvant effect of cholera toxin on the mucosal immune response to soluble proteins. Scand J Immunol 1989;29:739-45.
11. Vázquez-Padrón RI, Moreno-Fierros L, Neri-Bazán L, de la Riva GA, López-Revilla R. Intragastric and intraperitoneal administration of Cry1Ac protoxin from Bacillus thuringiensis induces systemic and mucosal antibody responses in mice. Life Sci 1999; 64:1897-912.
12. Vázquez-Padrón RI, Moreno-Fierros L, Neri-Bazán L, de la Riva GA, López-Revilla R. Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant. Scand J Immunol 1999;49:578-84.
13. Ge AZ, Pfister RM, Dean DH. Hyperexpression of a Bacillus thuringiensis delta-endotoxin-encoding gene in Escherichia coli: properties of the product. Gene 1990;93:49-54.
14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
15. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
16. Choma CT, Kaplan H. Folding and unfolding of the protoxin from Bacillus thuringiensis: evidence that the toxic moiety is present in an active conformation. Biochemistry 1990;29:10971-7.
17. Lees A, Nelson BL, Mond JJ. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological regents. Vaccine 1996;14:190-8.
18. Monsigny M, Petit C, Roche AC. Colorimetric determination of neutral sugar by a resorcinol sulfuric acid micromethod. Anal Biochem 1988;175:525-30.
19. Peeters CCAM, Lagerman PR, Weers O et al. Polysaccharide-conjugate vaccines. In: Methods in Molecular Medicine: Vaccine Protocols. A Robinson, GH Farrar, CM Wiblin, eds. Totowa, NJ: Humana Press, 1996, 111-33.
20. Hornbeck P. Indirect ELISA to detect specific antibodies. In: Current Protocols in Immunology. JE Coligan, AM Kruisbeek, DH Margulies, ET Saevach, W Struber, eds. New York: Wiley, 1996, 2.1-3.6.
21. Janoff EN, Rubins JB. Respiratory bacterial vaccines. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, eds. Handbook of Mucosal Immunology. 2nd edn. San Diego, CA: Academic Press, 1999, 881-94.
22. Bruyn GAW, Zegers BJM, Van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992;14:251-62.
23. Robbins JBR, Austrian CJ, Lee SC et al. Considerations for formulating the second-generation pneumococcal polysaccharide vaccine with emphasis on the cross-relative types within groups. J Infect Dis 1983;148:1136-59.
24. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992;14:801.
25. McGhee JR, Czerkinsky C, Mestecky J. Mucosal vaccines: an overview. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, eds. Handbook of Mucosal Immunology, 2nd edn. San Diego, CA: Academic Press, 1999, 741-57.
26. Baldridge JR, Yorgensen Y, Ward JR, Ulrich T. Monophosphoryl lipid A enhances mucosal and systemic to vaccine antigens following intranasal administration. Vaccine 2000;18:2416-25.
27. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-7.
28. Giebink GS. Preventing pneumococcal disease in children: recommendations for using pneumococcal vaccine. Pediatr Infect Dis J 1985;4:343-8.
29. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
30. Schneerson R, Robbins JB, Parke Jr JC et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986;52:519-28.
31. Sigurdardottir ST, Vidarsson G, Gudnason T et al. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr Infect Dis J 1997;16:667-74.
32. Powers DC, Anderson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996;173:1014-8.
33. Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997;65:242-7.
34. VanCott JL, Kobayashi T, Yamamoto M, Pillai S, McGhee JR, Kiyono H. Induction of pneumococcal polysaccharide-specific mucosal immune responses by oral immunization. Vaccine 1996;14:392-8.
35. Yao Q, Vuong V, Li M, Compans RW. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 2002;20:2537-45.
36. Abraham E, Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. Vaccine 1991;9:757.
37. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, eds. Handbook of Mucosal Immunology. 2nd edn. San Diego, CA: Academic Press, 1999, 817-38.
38. Xu-Amano J, Kiyono H, Jackson RJ et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1993;178:1309.
39. Xu-Amano J, Jackson RJ, Fujihashi K, Kiyono H, Staats HF, McGhee JR. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 1994;12:903.
40. McGhee JR, Mestecky J, Elson CO, Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol 1989;9:175-99.
41. Lebman DA, Fuhrman JA, Cebra JJ. Intraduodenal application of cholera holotoxin increases the potential of clones from Peyer's patch B cells of relevant and unrelated specificities to secrete IgG and IgA. Reg Immunol 1988;1:32-40.
42. Lycke N, Strober W. Cholera toxin promotes B cell isotype differentiation. J Immunol 1989;142:3781-7.
43. Vázquez-Padrón RI, Gonzáles-Cabrera J, García-Tovar L et al. Cry1Ac protoxin from Bacillus thuringiensis sp. kurstaki HD73 binds to surface proteins in the mouse small intestine. Biochem Biophys Res Commun 2000;271:54-8.
44. Lycke N, Karlsson U, Sjolander A, Magnusson KE. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol 1991;33:691-8.
45. Gizurarson S, Tamura S, Aizawa C, Kurata T. Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine 1992;10:101-6.
46. Takahashi I, Marinaro M, Kiyono H et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996;173:627-35.
47. Cong Y, Weaver CT, Elson CO. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol 1997;159:5301-8.
48. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 1997;148:504-20.
49. Marinaro M, Boyaka PN, Finkelman FD et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997;185:415-27.
50. Li T-K, Fox BS. Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokines production from a T cell clone. Int Immunol 1998;8:1849-56.
51. Jakobsen H, Schulz D, Pizza M, Rappuoli R, Jónsdóttir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect Immun 1999;67:5892-7.
52. 1. J Immunol 2002;168:3437-43.
53. Seong S, Cho N, Kwon I, Jeong S. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun 1999;67:3587-92.
54. Bergquist C, Lagergard T, Holmgren J. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect Immun 1997;65:1579-83.
55. Wu H-Y, Nahm MH, Guo Y, Russell MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997;175:839-46.
56. Johnson S, Opstad NL, Douglas Jr JM, Janoff EN. Prolonged and preferential production of polymeric immunoglobulin A in response to Streptococcus pneumoniae capsular polysaccharide. Infect Immun 1996;64:4339-44.
57. Korkeila M, Lehtonen H, Ahman H, Leroy O, Eskola J, Käyhty H. Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid. Vaccine 2000;18:1218-26.
58. Janoff EN, Fasching C, Orenstein JM, Rubins JB, Opstad NL, Dalmasso AP. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest 1999;104:1139-47.